Joao Gorgulho

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.

Journal: ESMO gastrointestinal oncology

Published: March 19, 2026

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.

Journal: Gut

Published: November 21, 2025

A dual compartment peripheral blood signature of soluble and membrane-bound immune checkpoints predicts outcome in lymphoma patients.

A dual compartment peripheral blood signature of soluble and membrane-bound immune checkpoints predicts outcome in lymphoma patients.

Journal: Oncoimmunology

Published: August 28, 2025

Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Journal: Annals of hepatology

Published: January 22, 2025

Red blood cell-tumor cell interactions promote tumor cell progression.

Red blood cell-tumor cell interactions promote tumor cell progression.

Journal: Journal of experimental & clinical cancer research : CR

Published: December 17, 2024

Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis.

Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis.

Journal: JHEP reports : innovation in hepatology

Published: October 14, 2024

Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients.

Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients.

Journal: Alimentary pharmacology & therapeutics

Published: September 12, 2024

Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma.

Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 05, 2024

Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy.

Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 06, 2024

Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.

Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.

Journal: Hepatology (Baltimore, Md.)

Published: May 02, 2024

Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade.

Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade.

Journal: Frontiers in immunology

Published: April 16, 2023

Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.

Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.

Journal: British journal of cancer

Published: February 05, 2023

Showing 1-12 of 19

Last Updated: 09/26/2026